Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of BCAX is 30 and suggests 79% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell